ArticlePloS one2026
Dried blood spot 3-year stability suitability for biomarker discovery and biobanking initiatives in companion animals.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dried blood spot (DBS) sampling is a rapid, cost-effective, and sustainable method that requires minimal processing. It can be performed using remnant blood samples from clinics or via pinprick at home. The DBS metabolome has similar discriminatory potential to the plasma metabolome, making it suitable for biomarker discovery. This study evaluated the suitability of DBS for long-term storage and its potential for biomarker discovery from companion animal (cats and dogs) biobanks using two different approaches. Objective 1 assessed whether two independent metabolic profiling analyses using duplicate DBS card samples, conducted three years apart would provide similar phenotype discrimination. Objective 2 evaluated the potential to combine independent metabolomics datasets through a bridging sample, facilitating insights from prospective biobanks and enabling the reuse of previously acquired data. Using 54 samples from 5 phenotypic classes (1 cat breed and 4 dog breeds), after three years of storage at -80°C, the DBS metabolome showed a 7% reduction (782-728 metabolites). A thorough investigation indicated that this was likely due to experimental variation rather than time-dependent sample instability. Despite data loss, classification remained consistent across independent datasets using various approaches. Hierarchical cluster analysis (HCA) demonstrated correct pairing of individuals between runs for 81% of individuals. Partial least squares-discriminant analysis and Random Forest (RF) utilized many of the same metabolites to discriminate between classes and RF also accurately predicted blinded samples with similar probability in both runs. RF and HCA analyses of merged data performed well, with RF correctly predicting breed for two blinded samples and HCA correctly pairing 76% of individuals. These findings indicate that quality control samples can be used to normalize independent metabolomics studies to a similar baseline enabling combined analysis at a future time. Overall, the data support DBS as a suitable sample for several years of storage in biobanks, with minimal data loss, making it viable for biomarker discovery. Implementing DBS sampling of remnant blood can accelerate research activities, and merging data through suitable bridging samples can enhance the reuse of metabolome data, providing additional biological and economic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.